^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | SY-5609 (CDK7 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Highly Selective and Potent Oral CDK7 Inhibitor Shows Robust Anti-Tumor Activity in Colorectal Cancer Models
Published date:
05/29/2020
Excerpt:
Syros scientists conducted a series of preclinical studies of SY-5609 in colorectal cancer cell lines, as well as in 30 independent patient-derived xenograft (PDX) models of colorectal cancer, including BRAF-mutant, KRAS-mutant and wild-type models….Potently inhibited proliferation and induced G2/M cell cycle arrest in KRAS- and BRAF-mutant colorectal cancer cell lines in vitro...Deeper responses, defined as ≥ 90 percent tumor growth inhibition, were observed more frequently in models with BRAF mutations (50 percent, 5/10) relative to KRAS-mutant...
